JP2024505274A5 - - Google Patents
Info
- Publication number
- JP2024505274A5 JP2024505274A5 JP2023547031A JP2023547031A JP2024505274A5 JP 2024505274 A5 JP2024505274 A5 JP 2024505274A5 JP 2023547031 A JP2023547031 A JP 2023547031A JP 2023547031 A JP2023547031 A JP 2023547031A JP 2024505274 A5 JP2024505274 A5 JP 2024505274A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- rmva
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144834P | 2021-02-02 | 2021-02-02 | |
| US63/144,834 | 2021-02-02 | ||
| PCT/US2022/014970 WO2022169895A1 (en) | 2021-02-02 | 2022-02-02 | Viral constructs for use in enhancing t-cell priming during vaccination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505274A JP2024505274A (ja) | 2024-02-05 |
| JP2024505274A5 true JP2024505274A5 (https=) | 2025-02-06 |
Family
ID=82741782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547031A Pending JP2024505274A (ja) | 2021-02-02 | 2022-02-02 | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240344082A1 (https=) |
| EP (1) | EP4288076A4 (https=) |
| JP (1) | JP2024505274A (https=) |
| KR (1) | KR20240001116A (https=) |
| CN (1) | CN117177763A (https=) |
| AU (1) | AU2022215566A1 (https=) |
| BR (1) | BR112023015467A2 (https=) |
| CA (1) | CA3206004A1 (https=) |
| IL (1) | IL304805A (https=) |
| MX (1) | MX2023009008A (https=) |
| TW (1) | TW202246514A (https=) |
| WO (1) | WO2022169895A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111533785B (zh) * | 2020-02-11 | 2022-03-08 | 北京市肿瘤防治研究所 | 靶向免疫检查点tim3结合肽及其应用 |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| WO2024206243A1 (en) * | 2023-03-24 | 2024-10-03 | Geovax. Inc. | Pan-betacoronavirus vaccines and uses thereof |
| WO2025072383A1 (en) * | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| CN117904069B (zh) * | 2024-01-04 | 2025-07-15 | 华中农业大学 | VirEN蛋白介导的DNA拼接和基因编辑方法 |
| GB202409284D0 (en) * | 2024-06-27 | 2024-08-14 | Univ Oxford Innovation Ltd | Mrna platform |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| ATE315660T1 (de) | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| US20100305002A1 (en) | 2009-04-27 | 2010-12-02 | Roswell Park Cancer Institute | Reagents and Methods for Producing Bioactive Secreted Peptides |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CN115300622A (zh) * | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| US10098950B2 (en) | 2016-09-15 | 2018-10-16 | Leidos, Inc. | PD-1 Peptide Inhibitors |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| EP3796891A4 (en) * | 2018-04-11 | 2022-04-20 | Precision Molecular Inc. | THERAPEUTIC CONSTRUCTS FOR TREATMENT OF CANCER |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| CA3168836A1 (en) | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
-
2022
- 2022-02-02 JP JP2023547031A patent/JP2024505274A/ja active Pending
- 2022-02-02 AU AU2022215566A patent/AU2022215566A1/en active Pending
- 2022-02-02 MX MX2023009008A patent/MX2023009008A/es unknown
- 2022-02-02 KR KR1020237029493A patent/KR20240001116A/ko active Pending
- 2022-02-02 CN CN202280021291.5A patent/CN117177763A/zh active Pending
- 2022-02-02 EP EP22750341.4A patent/EP4288076A4/en active Pending
- 2022-02-02 WO PCT/US2022/014970 patent/WO2022169895A1/en not_active Ceased
- 2022-02-02 CA CA3206004A patent/CA3206004A1/en active Pending
- 2022-02-02 BR BR112023015467A patent/BR112023015467A2/pt unknown
- 2022-02-07 TW TW111104426A patent/TW202246514A/zh unknown
-
2023
- 2023-07-27 IL IL304805A patent/IL304805A/en unknown
- 2023-08-01 US US18/229,070 patent/US20240344082A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024505274A5 (https=) | ||
| JP2022160401A5 (https=) | ||
| Nagai | Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding | |
| Ferko et al. | Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice | |
| Baron et al. | Rescue of rinderpest virus from cloned cDNA | |
| JP2025184979A5 (https=) | ||
| CN1989250B (zh) | Tc-83衍生的甲病毒属载体、颗粒和方法 | |
| Ohgimoto et al. | Sequence analysis of P gene of human parainfluenza type 2 virus: P and cysteine-rich proteins are translated by two mRNAs that differ by two nontemplated G residues | |
| AU2004245859B2 (en) | Cell surface expression vector of SARS virus antigen and microorganisms transformed thereby | |
| JP2007513634A5 (https=) | ||
| JP2022502077A5 (https=) | ||
| JPH09322781A5 (https=) | ||
| JP2002510494A5 (https=) | ||
| RU2733831C1 (ru) | Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2 | |
| JP2020534284A5 (https=) | ||
| JP2023542297A5 (https=) | ||
| WO2021207848A1 (en) | Mers-cov vaccine | |
| JP2023522708A5 (https=) | ||
| JP2025503468A5 (https=) | ||
| JPWO2020027010A5 (https=) | ||
| CN113430178B (zh) | 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用 | |
| CN114269939B (zh) | 汉坦病毒抗原组合物 | |
| EP1512693A3 (en) | Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof | |
| JP2020522249A5 (https=) | ||
| JP2022532917A5 (https=) |